
Strides Shasun has announced plans to sell Shasun Pharma to its current management, a provider of contract research and manufacturing services in the UK.
The sale consideration is expected to be approximately $36m and will be completed by September 2016.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Shanghai Fosun Pharma has announced a non-binding proposal to acquire Gland Pharma for a purchase consideration ranging between $1bn and $1.5bn.
The company expects that the acquisition will help develop its drug manufacturing and research and development (R&D) capacity.
Image: Shanghai Fosun Pharma expects that the acquisition will help develop its drug manufacturing and research and development (R&D) capacity. Photo: Courtesy of Shanghai Fosun Pharma.

US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData